ProCE Banner Activity

Acalabrutinib + Lenalidomide and Rituximab With MRD Monitoring in Previously Untreated Mantle Cell Lymphoma

Slideset Download
Conference Coverage

Addition of acalabrutinib to lenalidomide and rituximab as initial treatment of MCL was associated with high MRD-negative complete responses in this preliminary study.

Released: December 16, 2022

Expiration: December 15, 2023

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen